Hologic Appoints Wayde McMillan to Board of Directors
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment, has announced the election of Wayde McMillan to its Board of Directors, effective April 4, 2025. In addition to his appointment to the Board, Mr. McMillan will also serve as a member of the company’s Audit and Finance Committee, also effective April 4.
Mr. McMillan brings with him over two decades of financial and executive leadership experience, primarily within the healthcare and medical technology sectors. His extensive background in financial operations, investor relations, strategic planning, and operational oversight is expected to provide significant value to Hologic as the company continues to execute its growth strategy and maintain financial discipline while innovating in women’s health diagnostics, surgical, and medical imaging solutions.
A Strategic Appointment to Support Hologic’s Growth Trajectory
Steve MacMillan, Hologic’s Chairman, President, and Chief Executive Officer, expressed strong enthusiasm for Mr. McMillan’s addition to the board, stating, “We’re thrilled to welcome Wayde to Hologic’s Board of Directors. His extensive financial expertise and deep understanding of the med-tech industry will be great complements to our current Board. Wayde’s unique experience across leading healthcare companies and his ability to navigate complex financial and operational challenges will strengthen our governance and help us drive long-term value for our shareholders.”
The appointment of McMillan comes at a pivotal moment for Hologic as the company continues to expand its global footprint and product offerings across diagnostics, breast health, gynecologic surgical products, and medical aesthetics. Hologic’s focus on innovation, particularly in molecular diagnostics and digital imaging, benefits significantly from board members with robust backgrounds in both finance and medical technology leadership.
A Distinguished Career in Healthcare and Medical Technology
Wayde McMillan currently serves as the Chief Financial Officer of Solventum Corporation, a newly formed healthcare carve-out from 3M Company. Since assuming this role in 2024, he has led Solventum through its early-stage operations, helping to establish a strong financial foundation and growth trajectory for the spinout. His responsibilities include overseeing financial reporting, strategic financial planning, capital allocation, and investor engagement.
Prior to joining Solventum, McMillan was Chief Financial Officer of 3M’s Health Care Business Group, a position he held beginning in November 2023. In this capacity, he played a key leadership role during a critical period as 3M prepared to spin off its healthcare business into what is now Solventum Corporation. His financial acumen and strategic oversight were instrumental in shaping the structure, financial strategy, and go-to-market readiness of the new entity.
McMillan’s reputation as a seasoned healthcare executive was solidified during his tenure at Insulet Corporation, where he served as Executive Vice President, Chief Financial Officer, and Treasurer from March 2019 to November 2023. Insulet, a prominent medical device company known for its Omnipod® insulin management system, experienced significant growth and operational advancement under McMillan’s financial leadership. He played a key role in managing Insulet’s financial strategy through a dynamic period of expansion, navigating capital markets, scaling operations, and delivering strong financial results.
Prior to his time at Insulet, McMillan held a pivotal leadership role at Medtronic plc, where he served as Chief Financial Officer and Vice President of Finance for the Minimally Invasive Therapies Group (MITG) from January 2015 to February 2019. The MITG business, one of Medtronic’s largest groups at the time, was formed following Medtronic’s acquisition of Covidien plc. In this position, McMillan was responsible for integrating financial systems and strategies, streamlining operational efficiencies, and supporting Medtronic’s transformation initiatives in minimally invasive care.
Before joining Medtronic, McMillan built a solid foundation in finance and leadership over the course of nearly a decade at Covidien, where he held a series of senior financial leadership roles from 2006 until the company’s acquisition in 2015. At Covidien, a leading medical device and supplies company, he developed an in-depth understanding of corporate finance, investor relations, internal audit, and operational budgeting within the context of a fast-evolving healthcare landscape.
Earlier in his career, McMillan gained valuable experience in accounting, auditing, and financial analysis through a variety of roles at multiple institutions. This early stage of his professional journey helped him cultivate a strong command of financial best practices and regulatory compliance that would later inform his leadership at major healthcare companies.
Education and Professional Development
Mr. McMillan holds a Bachelor of Science degree in Business Administration from Merrimack College. He went on to earn a Master of Business Administration (MBA) from the McCallum Graduate School of Business at Bentley University, a program renowned for developing leaders with strong financial and strategic capabilities.
His academic foundation, combined with his practical experience in both public and private corporations, has positioned him as a highly respected executive within the healthcare finance community.
Enhancing Board Expertise in Med-Tech Finance and Corporate Governance
Hologic’s decision to appoint McMillan is aligned with the company’s broader objective of strengthening its Board with professionals who possess not only extensive financial backgrounds but also a strategic understanding of the healthcare and medical device ecosystem. McMillan’s insights into portfolio management, corporate carve-outs, mergers and acquisitions, and investor relations are expected to contribute to effective board oversight and high-level strategic decision-making.
The addition of McMillan to the Audit and Finance Committee further emphasizes Hologic’s commitment to rigorous financial governance, risk management, and transparent reporting practices. As a member of the committee, he will collaborate closely with other board members and executive leadership to ensure that the company maintains its strong track record of financial performance, integrity, and regulatory compliance.
The election of Wayde McMillan to Hologic’s Board of Directors marks another step forward for the company as it continues to build a leadership team capable of navigating the rapidly evolving landscape of women’s health and medical technology. With his broad-ranging experience in finance, strategic planning, and healthcare operations, McMillan is expected to bring a unique and valuable perspective to the Board.
As Hologic looks ahead to its next chapter of growth, innovation, and global impact, the expertise and leadership of individuals like Wayde McMillan will be essential in guiding the company through complex challenges and toward continued success.
